23 Oct 2013 Posted in ABPI statement By Press Office
This commitment is recognition that access to information in clinical study reports and patient level datasets may provide important opportunities to conduct future research that can help advance medical science or patient care.
The ABPI has been actively involved in accelerating the pace of improvements in clinical trial transparency by running and participating in workshops with healthcare stakeholders and launching a clinical trial disclosure toolkit to assist companies. In addition, the ABPI will undertake monitoring of compliance with the existing transparency requirements of the ABPI Code of Practice for medicines approved since 2012.
As part of a global industry, we are actively engaging with our European and international counterparts to input into on-going discussions around clinical trial transparency, and we look forward to continuing to contribute to this important area.
Tel: +44 (0) 20 7747 1441
Mobile: +44 (0) 7850 312064
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.